查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1666168

全球乳房影像市场 - 2025 至 2033 年

Global Breast Imaging Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024 年全球乳房影像市场规模达到 47.4 亿美元，预计到 2033 年将达到 97.7 亿美元，2025-2033 年预测期内的复合年增长率为 8.43%。

乳房影像涵盖多种诊断技术，旨在观察和评估乳房组织以识别肿块、囊肿或乳癌迹像等异常情况。这些方法对于早期发现、诊断和监测乳房疾病至关重要，有助于及时有效地采取治疗干预措施。

市场动态：

驱动因素与约束因素

科技进步日新月异

乳房影像技术的进步透过提高诊断准确性、改善患者治疗效果和增加可近性，极大地推动了市场成长。数位乳房 X 光摄影、3D 断层合成和人工智慧增强成像等技术能够实现更早、更精确的检测，即使在緻密的乳房组织中也是如此，同时最大限度地减少假阳性。例如，2024 年 8 月，OSF HealthCare 在其秘鲁圣伊丽莎白医疗中心推出了 Invenia ABUS 2.0（自动乳房超音波系统），标誌着乳癌筛检领域的重大技术进步。 Invenia ABUS 2.0 专门用于检测因乳房组织密度而可能隐藏在乳房 X 光检查照片中的癌症，在乳房 X 光检查照片中，緻密组织和癌变肿块均呈现白色。

同样，2022年6月，Seno Medical的Imagio乳房影像系统获得了美国食品药物管理局（FDA）设备和放射健康中心（CDRH）的补充上市前批准（PMA）。 Seno Medical 的 Imagio 乳房成像系统代表了乳房成像领域的重大技术进步，该创新系统利用光声 (OA) 和超音波 (US) 技术的组合来提供有关乳房病变的即时资讯。

此外，随着医疗保健提供者和患者认识到早期和准确诊断的重要性，对先进解决方案的需求正在激增。随着技术的进步，全球范围内获取高品质成像的机会正在改善，包括服务不足的地区。对新影像模式和人工智慧应用的持续研究进一步推动了市场成长，确保更多女性能够从早期检测计划中受益，并促进乳癌检测和治疗的持续进步。

乳房成像系统成本高昂

与乳房成像系统相关的高成本对市场的成长构成了重大挑战。例如，数位乳房 X 光摄影系统的价格范围从 65,000 美元到 95,000 美元不等，具体取决于型号和製造商。购买和维护数位乳房 X 光摄影机、MRI 系统和 3D 断层合成设备等设备需要大量的前期投资，这可能会给医院、诊所和医疗保健提供者带来沉重的财务负担。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动态

  • 影响因素
    • 驱动程式
      • 科技进步日新月异
    • 限制
      • 乳房成像系统成本高昂
    • 机会
  • 影响分析

第五章：战略洞察与产业展望

  • 市场领导者和先驱者
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的成熟领导者
    • 拥有成熟产品的市场领导者
  • CXO 观点
  • 最新进展与突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT 分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态
  • 关键意见领袖

第 6 章：按类型

  • 乳房X光检查
  • 诊断性乳房X光检查
  • 乳房断层合成
  • 乳房超音波检查
  • 乳房 MRI

第 7 章：按技术

  • 电脑断层扫描 (CT)
  • 磁振造影（MRI）扫描
  • 超音波
  • 正子断层扫描 (PET)
  • 其他的

第 8 章：按应用

  • 乳房疾病
  • 乳癌
  • 良性肿瘤
  • 囊肿
  • 其他的

第 9 章：按最终用户

  • 医院
  • 诊断中心
  • 研究机构
  • 其他的

第 10 章：按地区

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局

  • 竞争格局
  • 市场定位/份额分析
  • 併购分析

第 12 章：公司简介

  • GE HealthCare
    • 公司概况
    • 产品组合
      • 产品描述
      • 产品关键绩效指标 (KPI)
      • 历史和预测产品销售量
      • 产品销售量
    • 财务概览
      • 公司收入
      • 地区收入份额
      • 收入预测
    • 主要进展
      • 合併与收购
      • 关键产品开发活动
      • 监管部门批准等
    • SWOT 分析
  • Koning Health
  • FUJIFILM Holdings Corporation
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Hologic, Inc.
  • Siemens Healthineers AG
  • Agfa-Gevaert Group.
  • Koninklijke Philips NV
  • Planmed Oy
  • Seno Medical
  • Similar data will be provided for each market player.

第 13 章：附录

简介目录
Product Code: MI878

The global breast imaging market reached US$ 4.74 billion in 2024 and is expected to reach US$ 9.77 billion by 2033, growing at a CAGR of 8.43% during the forecast period 2025-2033.

Breast imaging encompasses a variety of diagnostic techniques aimed at visualizing and evaluating breast tissue to identify abnormalities such as lumps, cysts, or signs of breast cancer. These methods are essential for early detection, diagnosis, and monitoring of breast conditions, thereby facilitating timely and effective treatment interventions.

Market Dynamics: Drivers & Restraints

Rising technological advancements

Advancements in breast imaging technologies are significantly propelling market growth by enhancing diagnostic accuracy, improving patient outcomes, and increasing accessibility. Technologies like digital mammography, 3D tomosynthesis, and AI-enhanced imaging enable earlier and more precise detection, even in dense breast tissue, while minimizing false positives. For instance, in August 2024, OSF HealthCare introduced the Invenia ABUS 2.0 (Automated Breast Ultrasound System) at its Saint Elizabeth Medical Center in Peru, marking a significant technological advancement in breast cancer screening. The Invenia ABUS 2.0 is specifically designed to detect cancers that may be hidden on mammograms due to the density of breast tissue, where both dense tissue and cancerous masses appear white.

Similarly, in June 2022, Seno Medical's Imagio Breast Imaging System received supplemental premarket approval (PMA) from the Center for Devices and Radiological Health (CDRH) of the US Food & Drug Administration (FDA). The Imagio Breast Imaging System by Seno Medical represents a significant technological advancement in breast imagingThis innovative system utilizes a combination of opto-acoustic (OA) and ultrasound (US) technologies to provide real-time information about breast lesions.

Additionally, the demand for advanced solutions is surging as healthcare providers and patients recognize the importance of early and accurate diagnosis. As technology progresses, access to high-quality imaging is improving globally, including in underserved regions. Continuous research into new imaging modalities and AI applications further propels market growth, ensuring more women can benefit from early detection initiatives and fostering ongoing advancements in breast cancer detection and treatment.

High costs associated with breast imaging systems

The high costs associated with breast imaging systems present a significant challenge to the growth of the market. For instance, digital mammography systems can range from $65,000 to $95,000, depending on the model and manufacturer. The high upfront investment required for purchasing and maintaining equipment such as digital mammography machines, MRI systems, and 3D tomosynthesis devices can be a significant financial burden for hospitals, clinics, and healthcare providers.

Segment Analysis

The global Breast Imaging market is segmented based on technology, end-user, and region.

Technology:

Magnetic resonance imaging (MRI) segment is expected to dominate the global Breast Imaging market share

The Magnetic Resonance Imaging (MRI) segment dominates the breast imaging market due to its advanced imaging capabilities and non-invasive nature. Innovations such as 3D MRI and contrast-enhanced MRI significantly enhance the effectiveness of breast cancer detection, particularly for women with dense breast tissue or those at high risk. For instance, in October 2022, Intermountain Healthcare is launching an abbreviated MRI screening tool specifically designed for women at higher risk of developing breast cancer. This development marks a significant advancement in the MRI segment of breast imaging, as it offers a targeted approach to enhance early detection in populations that may not benefit as much from traditional mammography. These advancements allow healthcare providers to deliver more accurate and detailed diagnostic options, leading to improved patient outcomes. The high sensitivity and specificity of MRI are crucial for early detection and effective management of breast cancer, making it a preferred choice in clinical settings.

The increasing prevalence of breast cancer drives the adoption of MRI in breast imaging. According to the World Health Organization report, In 2022, there were 2.3 million women diagnosed with breast cancer. The incidence is expected to increase which is increasing the urgent need for advanced imaging technologies like MRI. As healthcare systems emphasize early detection and preventive care, the demand for MRI continues to rise, positioning it as a leading segment in the breast imaging market. The combination of technological advancements and growing awareness about breast cancer screening underscores MRI's pivotal role in enhancing diagnostic capabilities and improving patient care.

Geographical Analysis

North America is expected to hold a significant position in the global breast imaging market share

North America is expected to hold a significant position in the global breast imaging market due to several key factors. Advancements in medical technology, particularly in imaging techniques like 3D mammography, ultrasound, and MRI, are crucial factors in maintaining North America's dominant position in the breast imaging market. As these technologies evolve, healthcare providers in the region can offer more precise, non-invasive, and effective diagnostic options.

The region's continued development of cutting-edge technologies helps solidify its leadership in the global breast imaging market, ensuring that healthcare providers have access to the latest tools for early detection and improved treatment. For instance, Seno Medical Instruments officially launched the commercially available Imagio Breast Imaging System at RSNA in November 2022, marking a significant development for breast cancer diagnostics in North America. This innovative system utilizes a combination of optoacoustic and ultrasound technology to provide real-time information about breast lesions, enabling radiologists to differentiate between benign and malignant masses more effectively.

Key market players are driving the growth of the breast imaging market in North America by focusing on technological advancements, strategic partnerships, and expanding their product portfolios. For instance, in December 2024, QT Imaging Holdings, Inc. announced the expansion of its Breast Acoustic CT Scanner to the Couri Center for Gynecology and Integrative Women's Health in Peoria, IL. This strategic initiative, executed in partnership with NXC Imaging, Inc., enhances access to innovative breast imaging technology that prioritizes patient comfort and safety while delivering high-quality diagnostic capabilities. The rising demand for breast imaging in both diagnostic and treatment applications has created significant growth opportunities for manufacturers in North America. Thus, the above factors are expected to hold the region in the dominant position.

Competitive Landscape

The major global players in the Breast Imaging market include Bayer AG, Pfizer, Inc., AbbVie, Inc, AstraZeneca, Gedeon Richter Plc., TORRENT PHARMACEUTICALS LTD., Sanofi SA, Gynogen, and Weefsel Pharma among others.

Key Developments

  • In August 2024, Izotropic Corporation announced that it is pursuing a regulatory strategy in the U.S. and EU to launch IzoView as a diagnostic device indicated for use in patients with dense breast tissue.
  • In June 2023, Koning Corporation launched adjunctive artificial intelligence (AI) software that can produce 3D CT breast images through seamless integration with the company's existing breast CT devices.
  • In January 2023, Izotropic Corporation announced that IzoView will be featured on an upcoming segment of Advancements with Ted Danson ("Advancements") via Amazon Prime Video and Bloomberg TV.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Breast Imaging Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Technology
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising technological advancements
    • 4.1.2. Restraints
      • 4.1.2.1. High costs associated with breast imaging systems
    • 4.1.3. Opportunity
  • 4.2. Impact Analysis

5. Strategic Insights and Industry Outlook

  • 5.1. Market Leaders and Pioneers
    • 5.1.1. Emerging Pioneers and Prominent Players
    • 5.1.2. Established leaders with largest selling Brand
    • 5.1.3. Market leaders with established Product
  • 5.2. CXO Perspectives
  • 5.3. Latest Developments and Breakthroughs
  • 5.4. Case Studies/Ongoing Research
  • 5.5. Regulatory and Reimbursement Landscape
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa
  • 5.6. Porter's Five Force Analysis
  • 5.7. Supply Chain Analysis
  • 5.8. Patent Analysis
  • 5.9. SWOT Analysis
  • 5.10. Unmet Needs and Gaps
  • 5.11. Recommended Strategies for Market Entry and Expansion
  • 5.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 5.13. Pricing Analysis and Price Dynamics
  • 5.14. Key Opinion Leaders

6. By Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Type
    • 6.1.2. Market Attractiveness Index, By Type
  • 6.2. Screening Mammography*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Diagnostic Mammography
  • 6.4. Breast Tomosynthesis
  • 6.5. Breast Ultrasound
  • 6.6. Breast MRIs

7. By Technology

  • 7.1. Introduction
    • 7.1.1. Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 7.1.2. Market Attractiveness Index, By Technology
  • 7.2. Computed Tomography (CT) Scan*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Magnetic Resonance Imaging (MRI) Scan
  • 7.4. Ultrasound
  • 7.5. Positron Emission Tomography (PET) Scan
  • 7.6. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Breast Disease*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Breast Cancers
  • 8.4. Benign Tumors
  • 8.5. Cysts
  • 8.6. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Research Institutes
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.5.1. U.S.
      • 10.2.5.2. Canada
      • 10.2.5.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.5.1. Germany
      • 10.3.5.2. U.K.
      • 10.3.5.3. France
      • 10.3.5.4. Spain
      • 10.3.5.5. Italy
      • 10.3.5.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.5.1. Brazil
      • 10.4.5.2. Argentina
      • 10.4.5.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.5.1. China
      • 10.5.5.2. India
      • 10.5.5.3. Japan
      • 10.5.5.4. South Korea
      • 10.5.5.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

Key Market Players

  • 12.1. GE HealthCare*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio
      • 12.1.2.1. Product Description
      • 12.1.2.2. Product Key Performance Indicators (KPIs)
      • 12.1.2.3. Historic and Forecasted Product Sales
      • 12.1.2.4. Product Sales Volume
    • 12.1.3. Financial Overview
      • 12.1.3.1. Company Revenue's
      • 12.1.3.2. Geographical Revenue Shares
      • 12.1.3.3. Revenue Forecasts
    • 12.1.4. Key Developments
      • 12.1.4.1. Mergers & Acquisitions
      • 12.1.4.2. Key Product Development Activities
      • 12.1.4.3. Regulatory Approvals etc.
    • 12.1.5. SWOT Analysis
  • 12.2. Koning Health
  • 12.3. FUJIFILM Holdings Corporation
  • 12.4. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 12.5. Hologic, Inc.
  • 12.6. Siemens Healthineers AG
  • 12.7. Agfa-Gevaert Group.
  • 12.8. Koninklijke Philips N.V.
  • 12.9. Planmed Oy
  • 12.10. Seno Medical
  • Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us